Uterine inflammatory myofibroblastic tumor with THBS1-INSR fusion

Angela Sim; Mojgan Devouassoux-Shisheboran; Camélia Benmoulay-Rigollot; Tiphanie Picot; Michel Péoc'h; Georgia Karpathiou

doi:10.1016/j.prp.2023.154500

Uterine inflammatory myofibroblastic tumor with THBS1-INSR fusion

Pathol Res Pract. 2023 Jun:246:154500. doi: 10.1016/j.prp.2023.154500. Epub 2023 May 5.

Authors

Angela Sim¹, Mojgan Devouassoux-Shisheboran², Camélia Benmoulay-Rigollot³, Tiphanie Picot¹, Michel Péoc'h¹, Georgia Karpathiou⁴

Affiliations

¹ Pathology Department, University Hospital of Saint-Etienne, Saint-Etienne, France.
² Pathology Department, Hospices Civils de Lyon, University Claude Bernard, Lyon, France.
³ Gynecology and Obstetrics Department, University Hospital of Saint-Etienne, Saint-Etienne, France.
⁴ Pathology Department, University Hospital of Saint-Etienne, Saint-Etienne, France. Electronic address: gakarpath@yahoo.gr.

PMID: 37156213
DOI: 10.1016/j.prp.2023.154500

Abstract

Uterine inflammatory myofibroblastic tumors (IMTs) are rare and, as in other localisations, they are associated with ALK rearrangements and ALK immunohistochemical expression. They are more frequently found during pregnancy, and in this context, they show different characteristics compared to other uterine IMTs. Here, we report the case of a uterine IMT discovered during delivery, and being associated with a previously unreported THBS1-INSR fusion.

Keywords: ALK; INSR; Placenta; Pregnancy; THBS1; Uterus.

Publication types

Case Reports

MeSH terms

Anaplastic Lymphoma Kinase / metabolism
Antigens, CD
Female
Granuloma, Plasma Cell* / pathology
Humans
Pregnancy
Receptor, Insulin
Uterine Neoplasms* / pathology

Substances

Anaplastic Lymphoma Kinase
INSR protein, human
Receptor, Insulin
Antigens, CD